Imagio Breast Imaging System

by Seno Medical Instruments Inc.  · Based in United States → — Reducing negative biopsies Better patient experience Improved practice efficiency
General Surgery Oncology Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

The Imagio® Breast Imaging System by Seno Medical Instruments is an innovative medical imaging modality that combines laser light and conventional ultrasound technology (Opto-Acoustic/Ultrasound or OA/US) to provide real-time functional and anatomical images of the breast. This system is designed to aid clinicians in differentiating between malignant and benign breast tissue by revealing information about blood and oxygen concentration, which are key indicators of cancer. It integrates an AI-driven clinical decision support tool called SenoGram®, which assists radiologists in objectively assigning BI-RADS classifications and assessing the likelihood of malignancy (LOM). The Imagio system aims to increase diagnostic confidence, reduce the number of unnecessary biopsies, and streamline the breast cancer diagnostic pathway without using ionizing radiation or contrast agents.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Opto-Acoustic/Ultrasound (OA/US) technology for fused functional and anatomical imaging
  • AI-driven clinical decision support tool (SenoGramu00ae) for objective BI-RADS classification and LOM assessment
  • Real-time imaging to differentiate malignant and benign breast tissue
  • Non-invasive, no ionizing radiation, and no contrast agents
  • Designed to reduce unnecessary breast biopsies and diagnostic workups
  • Provides information on blood oxygenation and vascularity within breast masses
  • Suitable for assessment of BI-RADS 3, 4a, and 4b masses
  • Demonstrated improved specificity without significant loss of sensitivity
  • Capable of differentiating masses as small as 3.5 mm
  • Enhances diagnostic confidence for clinicians at the point of care

Use Cases

  • Diagnostic evaluation of palpable and non-palpable breast lesions
  • Reducing false positive breast biopsies
  • Assessing and refining BI-RADS classifications
  • Adjunctive imaging for suspicious areas identified by mammography or ultrasound
  • Differentiating benign from malignant breast tissue without invasive procedures
  • Improving diagnostic confidence and efficiency in breast cancer care pathways

What Physicians Need to Know

Key Capabilities
The Imagio Breast Imaging System combines opto-acoustic (OA) technology with traditional ultrasound to provide fused functional and anatomical images of the breast. It visualizes two hallmark indicators of cancer: angiogenesis (new blood vessel formation) and hypoxia (reduced oxygen content in blood). The system also includes an AI decision-support tool called SenoGram® to assist physicians in interpreting images and assigning the likelihood of malignancy. It is non-invasive, does not use ionizing radiation or contrast agents, and does not require breast compression.
Clinical Utility
The Imagio system helps physicians differentiate between benign and malignant breast lesions, potentially reducing unnecessary biopsies caused by false-positive diagnostic assessments. It can provide real-time information, allowing for same-day results and reducing patient anxiety. The system is indicated for evaluating palpable and non-palpable breast abnormalities in adult patients referred for diagnostic imaging work-up following clinical presentation or other imaging examinations like screening mammography.
Integration Options
The Imagio system is designed to integrate into existing diagnostic workflows with minimal disruption, similar to how tomosynthesis was introduced.
Compliance Status
The Imagio Breast Imaging System (Model 9100) has received Premarket Approval (PMA) from the U.S. FDA in January 2021, with a supplemental PMA approval for its latest device in June 2022. It also received CE Mark certification under the European Union's Medical Device Regulation (EU MDR) in January 2026, enabling commercial launch in Europe.
Pricing Model
A study presented at RSNA in November 2023 found the Imagio® Breast Imaging System to be more cost-effective compared to ultrasound alone in evaluating suspicious breast lesions. The American Medical Association (AMA) issued a new Category III CPT code (0857T) for the use of the Imagio system, effective January 1, 2024, providing a means for coverage and reimbursement.
User Experience
The system aims to reduce patient stress, worry, and discomfort by providing faster answers and potentially avoiding unnecessary biopsies. It offers a non-invasive scan that looks and feels like a traditional ultrasound. Seno Medical provides training and certification, including an online platform (Seno University) and on-site training by a Clinical Applications Specialist, to help radiologists transition to OA/US imaging.
Support Quality
Seno Medical provides a training program accessible online at Seno University and on-site training by a Clinical Applications Specialist. The company offers a limited warranty for its products and recommends a six-month preventive maintenance schedule. All service work must be performed by an authorized service representative.
Implementation Complexity
Incorporating Imagio into a practice is described as similar to implementing tomosynthesis, with training and support provided to ensure a smooth transition.
Evidence Base
The Imagio system's efficacy is supported by studies such as the PIONEER Phase III pivotal trial, which found OA/US to be more specific than grayscale ultrasound alone in differentiating malignant from benign breast lesions, with non-inferior sensitivity. The Imagio Pivotal Study, an independent reader study, concluded that the system reduces false positives and biopsies of benign masses compared to grayscale ultrasound alone at an equivalent sensitivity. A study presented at RSNA in November 2023 also highlighted its cost-effectiveness.
Physician Tip

Leverage the SenoGram® AI decision-support tool to objectively assess the likelihood of malignancy, which can enhance diagnostic accuracy and confidence. The system's ability to provide real-time functional and anatomical information without radiation or contrast agents can significantly reduce patient anxiety and potentially avoid unnecessary biopsies. Integrate the Imagio system into existing workflows, as it is designed for minimal disruption, and utilize the provided training and certification to maximize its benefits.

The Imagio Breast Imaging System is designed to integrate into existing diagnostic workflows without requiring changes to screening protocols or replacing biopsy when clinically indicated. Its adoption is compared to the implementation of tomosynthesis, suggesting a familiar integration process for imaging centers.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentOn-premise (medical imaging system)
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties General Surgery, Oncology, Radiology

Support & Reliability

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2021-01-11P200003 PMAImagio Breast Imaging System

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Imagio Breast Imaging System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Imagio Breast Imaging System.

Loading videos...

View all on YouTube

Frequently Asked Questions

The Imagio Breast Imaging System integrates AI through its SenoGram® decision support tool, which assists clinicians in assessing the likelihood of malignancy (LOM) and accurately assigning BI-RADS classifications. This AI-driven analysis, combined with opto-acoustic and ultrasound imaging, provides functional biological data and imaging appearance to help distinguish masses and potentially reduce unnecessary biopsies.
The Imagio Breast Imaging System (Model 9005) received Premarket Approval (PMA) from the FDA for commercial distribution in the U.S. in 2021, with supplemental approval in 2022 for an advanced ultrasound technology integrated version (Model 9100). It also received the CE Mark in Europe in April 2014, and the next-generation Model 9100 obtained CE Mark certification under EU MDR in January 2026, allowing its sale and marketing in the European Union.
Traditional breast imaging alternatives include mammography, which is the gold standard for screening but involves ionizing radiation and compression, and conventional ultrasound, which is safe but operator-dependent. MRI is another option, offering detailed imaging but is expensive, time-intensive, and not suitable for all patients. The Imagio system aims to provide a non-invasive, radiation-free alternative that offers more diagnostic confidence than traditional ultrasound alone.
The Imagio Breast Imaging System is not indicated for ultrasound BI-RADS 1 and 2 findings. It should not be used in pregnant individuals, those with open sores on the breast, or patients experiencing phototoxicity due to certain medications or photosensitive diseases. While it improves diagnostic specificity, it is not intended as a replacement for mammographic screening or definitive pathological diagnosis.
The Imagio system combines opto-acoustic technology with ultrasound and AI to provide real-time functional and anatomical information about suspicious breast masses, including angiogenesis and oxygen levels. This additional information helps physicians more precisely diagnose or rule out breast cancer, potentially leading to fewer false positives and reducing the need for invasive biopsies, especially for BI-RADS 3-5 masses.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-13 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.